Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
07 2023
Historique:
received: 22 12 2022
accepted: 23 05 2023
medline: 21 7 2023
pubmed: 6 7 2023
entrez: 5 7 2023
Statut: ppublish

Résumé

In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. We show that long-lived CAR-T cells developed a CD4/CD8 double-negative phenotype with an exhausted-like memory state and distinct transcriptional signature. This persistence signature was dominant among circulating CAR-T cells in all children with a long-lived treatment response for which sequencing data were sufficient (4/4, 100%). The signature was also present across T cell subsets and clonotypes, indicating that persisting CAR-T cells converge transcriptionally. This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. Examination of single T cell transcriptomes from a wide range of healthy and diseased tissues across children and adults indicated that the persistence signature may be specific to long-lived CAR-T cells. These findings raise the possibility that a universal transcriptional signature of clinically effective, persistent CD19 CAR-T cells exists.

Identifiants

pubmed: 37407840
doi: 10.1038/s41591-023-02415-3
pii: 10.1038/s41591-023-02415-3
pmc: PMC10353931
doi:

Substances chimiques

Antigens, CD19 0
Receptors, Antigen, T-Cell 0
CD19 molecule, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1700-1709

Subventions

Organisme : Wellcome Trust
ID : 223135/Z/21/Z
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108413/A/15/D
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Maloney, K. W. et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children’s Oncology Group trial AALL0331. J. Clin. Oncol. 38, 602–612 (2020).
pubmed: 31825704
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
pubmed: 25317870 pmcid: 4267531
Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408–1414 (2019).
pubmed: 31477906
Xu, X. et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front. Immunol. 10, 2664 (2019).
Sheih, A. et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11, 219 (2020).
pubmed: 31924795 pmcid: 6954177
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
pubmed: 33020644 pmcid: 8446909
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4
pubmed: 35110735 pmcid: 9166916
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587 (2021).
pubmed: 34062119 pmcid: 8238499
Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc. Natl Acad. Sci. USA 116, 11906–11915 (2019).
pubmed: 31118283 pmcid: 6576116
Lee, M. S., Hanspers, K., Barker, C. S., Korn, A. P. & McCune, J. M. Gene expression profiles during human CD4
Galletti, G. et al. Two subsets of stem-like CD8
pubmed: 33046887 pmcid: 7610790
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8
pubmed: 31207603 pmcid: 6713202
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
pubmed: 31207604 pmcid: 7698992
Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 565–569 (2019).
Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8
pubmed: 25680272
Quigley, M. et al. Transcriptional analysis of HIV-specific CD8
pubmed: 20890291
Shin, H. et al. A role for the transcriptional repressor Blimp-1 in CD8
pubmed: 19664943
Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840–855 (2019).
pubmed: 31606264
Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293–300 (2019).
pubmed: 31802004
Biasco, L. et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat. Cancer 2, 629–642 (2021).
pubmed: 34345830 pmcid: 7611448
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
pubmed: 27124452 pmcid: 4944528
Young, M. D. et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 361, 594–599 (2018).
pubmed: 30093597 pmcid: 6104812
Li, X. et al. Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell leukemia. Mol. Ther. 29, 645–657 (2021).
pubmed: 33278564
Jardine, L. et al. Blood and immune development in human fetal bone marrow and Down syndrome. Nature 598, 327–331 (2021).
pubmed: 34588693 pmcid: 7612688
Park, J. E. et al. A cell atlas of human thymic development defines T cell repertoire formation. Science 367, eaay3224 (2020).
pubmed: 32079746 pmcid: 7611066
Kildisiute, G. et al. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Sci. Adv. 7, eabd3311 (2021).
pubmed: 33547074 pmcid: 7864567
Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789 (2019).
pubmed: 30595452
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
pubmed: 31359002 pmcid: 6689255
Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997 (2018).
pubmed: 30388455 pmcid: 6410377
Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308 (2018).
pubmed: 29961579 pmcid: 6348010
Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018).
pubmed: 29942094
Lee, H. O. et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat. Genet. 52, 594–603 (2020).
pubmed: 32451460
Liu, Y. et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat. Commun. 12, 741 (2021).
pubmed: 33531485 pmcid: 7854640
Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).
pubmed: 34914499
Dourthe, M. E. et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia 35, 3383–3393 (2021).
pubmed: 34002027
van Waart, H. et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J. Clin. Oncol. 33, 1918–1927 (2015).
pubmed: 25918291
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
pubmed: 33626253
Li, J., Lu, E., Yi, T. & Cyster, J. G. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature 533, 110–114 (2016).
pubmed: 27147029
Utzschneider, D. T. et al. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat. Immunol. 21, 1256–1266 (2020).
pubmed: 32839610
Utzschneider, D. T. et al. T cell factor 1-expressing memory-like CD8
pubmed: 27533016
Siddiqui, I. et al. Intratumoral Tcf1
pubmed: 30635237
Miller, B. C. et al. Subsets of exhausted CD8
pubmed: 30778252 pmcid: 6673650
Delpoux, A., Lai, C. Y., Hedrick, S. M. & Doedens, A. L. FOXO1 opposition of CD8
pubmed: 28973925 pmcid: 5651728
Michelini, R. H., Doedens, A. L., Goldrath, A. W. & Hedrick, S. M. Differentiation of CD8 memory T cells depends on Foxo1. J. Exp. Med. 210, 1189–1200 (2013).
pmcid: 3674697
Khabirova, E. et al. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia. Nat. Med. 28, 743–751 (2022).
pubmed: 35288693 pmcid: 9018413
Custers, L. et al. Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. Nat. Commun. 12, 1407 (2021).
pubmed: 33658498 pmcid: 7930245
Anderson, N. D. Transcriptional signatures associated with persisting CD19 CAR T-cells in children with leukaemia. https://doi.org/10.5281/ZENODO.7937878 (2023).

Auteurs

Nathaniel D Anderson (ND)

Wellcome Sanger Institute, Hinxton, UK.

Jack Birch (J)

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK.

Theo Accogli (T)

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK.

Ignacio Criado (I)

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK.

Eleonora Khabirova (E)

Wellcome Sanger Institute, Hinxton, UK.

Conor Parks (C)

Wellcome Sanger Institute, Hinxton, UK.

Yvette Wood (Y)

Wellcome Sanger Institute, Hinxton, UK.

Matthew D Young (MD)

Wellcome Sanger Institute, Hinxton, UK.

Tarryn Porter (T)

Wellcome Sanger Institute, Hinxton, UK.

Rachel Richardson (R)

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK.
Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK.

Sarah J Albon (SJ)

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK.
Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK.

Bilyana Popova (B)

Cancer Research UK & UCL Cancer Trials Centre, London, UK.

Andre Lopes (A)

Cancer Research UK & UCL Cancer Trials Centre, London, UK.

Robert Wynn (R)

Department of Bone Marrow Transplantation, Royal Manchester Children's Hospital, Manchester, UK.

Rachael Hough (R)

Children and Young People's Cancer Service, University College London Hospitals NHS Foundation Trust, London, UK.

Satyen H Gohil (SH)

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Department of Haematology, UCL Cancer Institute, London, UK.

Martin Pule (M)

Department of Haematology, UCL Cancer Institute, London, UK.

Persis J Amrolia (PJ)

Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK.
Department of Bone Marrow Transplantation, Great Ormond Street Hospital for Children, London, UK.

Sam Behjati (S)

Wellcome Sanger Institute, Hinxton, UK. sb31@sanger.ac.uk.
Department of Paediatrics, University of Cambridge, Cambridge, UK. sb31@sanger.ac.uk.
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. sb31@sanger.ac.uk.

Sara Ghorashian (S)

Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK. s.ghorashian@ucl.ac.uk.
Department of Haematology, Great Ormond Street Hospital for Children, London, UK. s.ghorashian@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH